JP2006502172A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006502172A5 JP2006502172A5 JP2004535514A JP2004535514A JP2006502172A5 JP 2006502172 A5 JP2006502172 A5 JP 2006502172A5 JP 2004535514 A JP2004535514 A JP 2004535514A JP 2004535514 A JP2004535514 A JP 2004535514A JP 2006502172 A5 JP2006502172 A5 JP 2006502172A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- guest molecule
- complex according
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical group CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 claims 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- MVPPADPHJFYWMZ-IDEBNGHGSA-N chlorobenzene Chemical group Cl[13C]1=[13CH][13CH]=[13CH][13CH]=[13CH]1 MVPPADPHJFYWMZ-IDEBNGHGSA-N 0.000 claims 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Substances ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical group FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 claims 1
- 229940078552 o-xylene Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241000242743 Renilla reniformis Species 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000035903 transrepression Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/241,658 US6777400B2 (en) | 2000-08-05 | 2002-09-11 | Anti-inflammatory androstane derivative compositions |
| PCT/EP2003/010259 WO2004024745A2 (en) | 2002-09-11 | 2003-09-09 | Complexes of 6.alpha. 9.alpha. - difluoro - 17. alpha. - [ (2 - furanylcarbonyl) oxy] - 11.beta. -hydroxy - 16- .alpha. -methyl - 3oxo- androsta- 1,4 -diene - 17 .beta. -carbothioic acid s-fluoromethyl ester |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006502172A JP2006502172A (ja) | 2006-01-19 |
| JP2006502172A5 true JP2006502172A5 (enExample) | 2006-06-22 |
Family
ID=31991223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004535514A Pending JP2006502172A (ja) | 2002-09-11 | 2003-09-09 | 抗炎症性または抗アレルギー性アンドロスタン複合体 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US6777400B2 (enExample) |
| EP (1) | EP1569951A2 (enExample) |
| JP (1) | JP2006502172A (enExample) |
| AU (1) | AU2003266390A1 (enExample) |
| WO (1) | WO2004024745A2 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ335276A (en) | 1996-10-18 | 2000-09-29 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease |
| GB0017988D0 (en) * | 2000-07-21 | 2000-09-13 | Glaxo Group Ltd | Novel process |
| US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| US6858596B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| US6777399B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| AU7649701A (en) | 2000-08-05 | 2002-02-18 | Glaxo Group Ltd | 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| CN1302007C (zh) * | 2001-04-30 | 2007-02-28 | 葛兰素集团有限公司 | 具有抗炎性的在17.α位上具有环酯基的雄甾烷的17.β.－硫代羧酸酯衍生物 |
| ES2307751T3 (es) * | 2001-06-12 | 2008-12-01 | Glaxo Group Limited | Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano. |
| GB0125259D0 (en) * | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
| US20050175545A1 (en) * | 2002-02-04 | 2005-08-11 | Keith Biggadike | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
| GB0202635D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| UY28500A1 (es) | 2003-09-05 | 2005-04-29 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc. |
| WO2005032521A2 (en) * | 2003-10-02 | 2005-04-14 | Collegium Pharmaceutical, Inc. | Non-flammable topical anesthetic liquid aerosols |
| US20060188449A1 (en) * | 2003-10-03 | 2006-08-24 | Jane Hirsh | Topical aerosol foams |
| KR101370580B1 (ko) * | 2004-06-08 | 2014-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | 약학 조성물 |
| GB0507165D0 (en) * | 2005-04-08 | 2005-05-18 | Glaxo Group Ltd | Novel crystalline pharmaceutical product |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| DK1993360T3 (en) | 2005-12-28 | 2017-05-22 | Vertex Pharma | SOLID FORMS OF N- [2,4-BIS (1,1-DIMETHYLETHYL) -5-HYDROXYPHENYL] -1,4-DIHYDRO-4-OXOQUINOLIN-3-CARBOXAMIDE |
| US7780671B2 (en) * | 2006-01-23 | 2010-08-24 | Zimmer Technology, Inc. | Bone resection apparatus and method for knee surgery |
| CN101489557B (zh) | 2006-02-27 | 2013-12-18 | 弗特克斯药品有限公司 | 包含vx-950的共晶体和包含所述共晶体的药物组合物 |
| NZ571280A (en) | 2006-03-16 | 2011-10-28 | Vertex Pharma | Deuterated hepatitis C protease inhibitors |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| ES2580803T3 (es) | 2006-04-07 | 2016-08-26 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| HRP20120330T1 (hr) * | 2007-02-27 | 2012-05-31 | Vertex Pharmaceuticals Incorporated | Sukristali i farmaceutski pripravci koji ih sadrže |
| EP2134717A2 (en) | 2007-02-27 | 2009-12-23 | Vertex Pharmceuticals Incorporated | Inhibitors of serine proteases |
| NZ583699A (en) * | 2007-08-30 | 2012-04-27 | Vertex Pharma | Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same |
| US8652443B2 (en) * | 2008-02-14 | 2014-02-18 | Precision Dermatology, Inc. | Foamable microemulsion compositions for topical administration |
| WO2010016931A2 (en) * | 2008-08-07 | 2010-02-11 | Plus Chemicals Sa | Polymorphs of fluticasone furoate and process for preparation thereof |
| WO2010108107A1 (en) | 2009-03-19 | 2010-09-23 | Plus Chemicals Sa | Polymorphs of fluticasone furoate and processes for preparation thereof |
| MX345541B (es) | 2010-03-25 | 2017-02-03 | Vertex Pharma | Formas solidas de (r)-1(2,2-difluorobenzo[d] [1,3]dioxol-5-il)-n-( 1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il) -1h-indol-5-il) ciclopropanocarboxamida. |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| CA2796646A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| KR20190061096A (ko) | 2010-04-22 | 2019-06-04 | 버텍스 파마슈티칼스 인코포레이티드 | 시클로알킬카르복스아미도-인돌 화합물의 제조 방법 |
| EP3138563A1 (en) | 2010-04-22 | 2017-03-08 | Vertex Pharmaceuticals Inc. | Pharmaceutical compositions and administrations thereof |
| EP2560650A1 (en) | 2010-04-22 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| WO2012009609A1 (en) | 2010-07-15 | 2012-01-19 | Battelle Memorial Institute | Biobased polyols for potential use as flame retardants in polyurethane and polyester applications |
| JP2013536231A (ja) | 2010-08-23 | 2013-09-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | （ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与 |
| CA2874851A1 (en) | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cftr-mediated disorders |
| CA2878057A1 (en) | 2012-07-16 | 2014-01-23 | Rossitza Gueorguieva Alargova | Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| ES3009747T3 (en) | 2012-11-02 | 2025-03-31 | Vertex Pharma | Pharmaceutical compositions for the treatment of cftr mediated diseases |
| US10206877B2 (en) | 2014-04-15 | 2019-02-19 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
| WO2019010092A1 (en) | 2017-07-01 | 2019-01-10 | Vertex Pharmaceuticals Incorporated | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS |
| CA3078893A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
| US20210228489A1 (en) | 2017-12-04 | 2021-07-29 | Vertex Pharmaceuticals Incorporated | Compositions for treating cystic fibrosis |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| CN111662353A (zh) * | 2019-03-05 | 2020-09-15 | 上海谷森医药有限公司 | 一种糠酸氟替卡松晶型1的制备方法 |
| UY38696A (es) | 2019-05-14 | 2020-11-30 | Vertex Pharma | Moduladores de alfa-1 antitripsina |
| WO2020242935A1 (en) | 2019-05-29 | 2020-12-03 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| US11304901B2 (en) | 2019-08-28 | 2022-04-19 | Anovent Pharmaceutical (U.S.), Llc | Liposome formulation of fluticasone furoate and method of preparation |
| MX2023005589A (es) | 2020-11-17 | 2023-07-31 | Vertex Pharma | Formas sólidas de ácido 4-(5-(4-fluorofenil)-6-(tetrahidro-2h-pira n-4-il)-1,5-dihidropirrolo[2,3-f]indazol-7-il)benzoico. |
| KR20240009433A (ko) | 2021-05-17 | 2024-01-22 | 사이빈 아이알엘 리미티드 | 실로시빈의 제형 |
| JP2024520649A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | （２ｒ，３ｓ，４ｓ，５ｒ）－４－［［３－（３，４－ジフルオロ－２－メトキシ－フェニル）－４，５－ジメチル－５－（トリフルオロメチル）テトラヒドロフラン－２－カルボニル］アミノ］ピリジン－２－カルボキサミドを含む固体剤形及び投与レジメン |
| US20250360148A1 (en) | 2022-06-22 | 2025-11-27 | Cybin Irl Limited | Solid dispersions of psilocybin |
| EP4565212A1 (en) | 2022-08-04 | 2025-06-11 | Vertex Pharmaceuticals Incorporated | Compositions for the treatment of cftr-mediated diseases |
| IL321269A (en) | 2022-12-06 | 2025-08-01 | Vertex Pharma | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| EP4648753A1 (en) | 2024-02-07 | 2025-11-19 | Vertex Pharmaceuticals Incorporated | Compositions for the treatment of cftr-mediated diseases |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR580494A (fr) | 1923-07-10 | 1924-11-07 | Const Metalliques Schiltigheim | Procédé d'établissement des buses d'aération ou autres tuyaux |
| US3067197A (en) | 1961-04-26 | 1962-12-04 | Pfizer & Co C | 11-oxygenated 6alpha-fluoro-16-methylene-delta-pregnenes and derivatives |
| US3639434A (en) | 1967-02-02 | 1972-02-01 | Boots Pure Drug Co Ltd | 17-acyloxysteroids and their manufacture |
| GB1384372A (en) | 1971-01-20 | 1975-02-19 | Glaxo Lab Ltd | Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids |
| US3828080A (en) | 1972-01-20 | 1974-08-06 | Glaxo Lab Ltd | Androstane-17beta-carboxylic acids and processes for the preparation thereof |
| US3989686A (en) | 1972-06-15 | 1976-11-02 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstane series and process for preparing same |
| GB1438940A (en) | 1972-07-19 | 1976-06-09 | Glaxo Lab Ltd | 17beta-haloalkoxycarbonyl-17alpha-oxysteroids |
| DE2336693A1 (de) | 1973-07-19 | 1975-02-06 | Nassheuer Ind Ofenbau Jean | Strahlheizrohr |
| US4093721A (en) | 1974-08-30 | 1978-06-06 | Glaxo Laboratories Limited | Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof |
| GB1517278A (en) | 1974-08-30 | 1978-07-12 | Glaxo Lab Ltd | Alkyl and haloalkyl androsta-1,4,15-triene and-4,15-diene-17beta-carboxylates |
| DE2538569A1 (de) | 1975-08-29 | 1977-03-03 | Siemens Ag | Verfahren zur metallisierung von duroplasten |
| CH628355A5 (de) | 1976-02-24 | 1982-02-26 | Ciba Geigy Ag | Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze. |
| US4261984A (en) | 1978-04-05 | 1981-04-14 | Syntex (U.S.A.) Inc. | 17β-thiocarboxylic acid esters of 3-oxo-4-halo-16β-methylandrost-4-enes |
| US4188385A (en) | 1978-04-05 | 1980-02-12 | Syntex (U.S.A.) Inc. | Thioetianic acid derivatives |
| US4187301A (en) | 1978-04-05 | 1980-02-05 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes |
| US4263289A (en) | 1978-04-05 | 1981-04-21 | Syntex (U.S.A.) Inc. | Thio etianic acid derivatives |
| US4198403A (en) | 1978-04-05 | 1980-04-15 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes |
| DE2817988A1 (de) | 1978-04-25 | 1979-11-08 | Hoechst Ag | Corticoid 17-alkylcarbonate und verfahren zu deren herstellung |
| US4310466A (en) | 1979-08-31 | 1982-01-12 | Syntex (U.S.A.) Inc. | Thio etianic acid derivatives |
| US4267173A (en) | 1979-11-05 | 1981-05-12 | Schering Corporation | Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor |
| US4335121A (en) | 1980-02-15 | 1982-06-15 | Glaxo Group Limited | Androstane carbothioates |
| US4996335A (en) | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
| SE449106B (sv) | 1980-07-10 | 1987-04-06 | Otsuka Pharma Co Ltd | Steroid med anti-inflammatorisk verkan samt komposition innehallande denna |
| US4710495A (en) | 1980-07-10 | 1987-12-01 | Otsuka Pharmaceutical Co., Ltd. | Soft steroids having anti-inflammatory activity |
| ATE8790T1 (de) | 1981-02-02 | 1984-08-15 | Schering Corporation | Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten. |
| ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| US4607028A (en) | 1983-08-18 | 1986-08-19 | Ciba-Geigy Corporation | Novel carboxylic acid esters |
| EP0179583A1 (en) | 1984-10-04 | 1986-04-30 | Merck & Co. Inc. | A system for enhancing the water dissolution rate and solubility of poorly soluble drugs |
| US4861765A (en) | 1985-06-26 | 1989-08-29 | Jouveinal | 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them |
| ZA872389B (en) | 1987-04-02 | 1987-11-25 | Advanced Polymer Systems Inc | Composition and method for delivering a steroid active ingredient |
| US4994439A (en) | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| IL95590A (en) | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
| DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| JP3087763B2 (ja) | 1990-11-30 | 2000-09-11 | 三井化学株式会社 | 新規な複素環式化合物およびそれを含有する医薬組成物 |
| GB9103764D0 (en) | 1991-02-22 | 1991-04-10 | Glaxo Group Ltd | Compositions |
| US5250293A (en) | 1991-04-22 | 1993-10-05 | Gleich Gerald J | Method for the treatment of hypersensitivity diseases by administration of anionic polymers |
| TW247878B (enExample) | 1991-07-02 | 1995-05-21 | Takeda Pharm Industry Co Ltd | |
| US6127353A (en) | 1991-09-06 | 2000-10-03 | Schering Corporation | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
| US5658549A (en) | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
| DE69413955T2 (de) | 1993-03-17 | 1999-04-01 | Minnesota Mining And Mfg. Co., Saint Paul, Minn. | Aerosolzusammensetzung enthaltend einen aus ester-, amid- oder merkaptoester- derivat dispergiermittel |
| DE4328819A1 (de) | 1993-08-27 | 1995-03-02 | Hoechst Ag | Corticosteroid-17-alkylcarbonat-21/0/-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| DE4333920A1 (de) | 1993-10-05 | 1995-04-13 | Hoechst Ag | Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| US5420120A (en) | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
| US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| IL109656A (en) | 1994-05-15 | 1998-02-22 | Chemagis Ltd | Process for the manufacture of androstane - 17 - carbothioates and androstane - 17 - carbothioates prepared thereby |
| GB9410222D0 (en) | 1994-05-21 | 1994-07-06 | Glaxo Wellcome Australia Ltd | Medicaments |
| GB9419536D0 (en) | 1994-09-28 | 1994-11-16 | Glaxo Inc | Medicaments |
| AR002009A1 (es) | 1994-12-22 | 1998-01-07 | Astra Ab | Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco. |
| DE19528145A1 (de) | 1995-08-01 | 1997-02-06 | Boehringer Ingelheim Kg | Neue Arzneimittel und ihre Verwendung |
| GB9521696D0 (en) | 1995-10-23 | 1996-01-03 | Bayer Ag | Combination of LTD4 receptor antagonists with glucocorticosteriods |
| US5707984A (en) | 1995-12-08 | 1998-01-13 | G. D. Searle & Co. | Steroid nitrite/nitrate ester derivatives useful as anti-inflammatory drugs |
| SK89198A3 (en) | 1995-12-29 | 1999-03-12 | Glaxo Group Ltd | Lactone derivatives of 17.beta.-carboxy, carbothio and amide androstane derivatives |
| US5981517A (en) | 1996-05-09 | 1999-11-09 | Soft Drugs, Inc. | Androstene derivatives |
| JPH11511758A (ja) | 1996-06-04 | 1999-10-12 | ザ、プロクター、エンド、ギャンブル、カンパニー | 鼻腔用ステロイドと抗ヒスタミン剤を含む鼻腔内噴霧薬 |
| GB9622173D0 (en) | 1996-10-24 | 1996-12-18 | Glaxo Group Ltd | Particulate Products |
| US5919776A (en) | 1996-12-20 | 1999-07-06 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
| US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| ES2239801T3 (es) | 1997-04-02 | 2005-10-01 | The Brigham And Women's Hospital, Inc. | Uso de un agente para disminuir el riesgo de enfermedad cardiovascular. |
| AU8439998A (en) | 1997-06-30 | 1999-01-25 | Glaxo Group Limited | Compounds |
| SE9704186D0 (sv) | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
| SE9704833D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New formulation |
| US5972920A (en) | 1998-02-12 | 1999-10-26 | Dermalogix Partners, Inc. | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders |
| US6136294C1 (en) | 1998-09-22 | 2002-09-24 | Aeropharm Technology Inc | Amino acid stabilized medical aerosol formulation |
| US6261539B1 (en) | 1998-12-10 | 2001-07-17 | Akwete Adjei | Medicinal aerosol formulation |
| GB9828721D0 (en) | 1998-12-24 | 1999-02-17 | Glaxo Group Ltd | Novel apparatus and process |
| AU3411000A (en) | 1999-03-24 | 2000-10-09 | Glenayre Electronics, Inc | Computation and quantization of voiced excitation pulse shapes in linear predictive coding of speech |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| JP2003508453A (ja) | 1999-08-31 | 2003-03-04 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | アテローム性動脈硬化疾患の予防における診断的ツールとしての全身性炎症マーカー |
| US7413536B1 (en) | 1999-09-14 | 2008-08-19 | Xenoport, Inc. | Substrates and screening methods for transport proteins |
| US6596261B1 (en) | 2000-01-25 | 2003-07-22 | Aeropharm Technology Incorporated | Method of administering a medicinal aerosol formulation |
| US20020133032A1 (en) | 2000-02-25 | 2002-09-19 | Jufang Barkalow | Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods |
| GB0009592D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory combinations |
| GB0009583D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
| GB0009591D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medical combinations |
| GB0009606D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Therapeutic combinations |
| TW519651B (en) | 2000-06-27 | 2003-02-01 | Intel Corp | Embedded security device within a nonvolatile memory device |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| GB0016040D0 (en) | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
| GB0017988D0 (en) | 2000-07-21 | 2000-09-13 | Glaxo Group Ltd | Novel process |
| US20020037877A1 (en) | 2000-07-26 | 2002-03-28 | Alcon Universal Ltd. | Pharmaceutical suspension compositions lacking a polymeric suspending agent |
| US6777399B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| AU7649701A (en) | 2000-08-05 | 2002-02-18 | Glaxo Group Ltd | 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| MXPA03002813A (es) | 2000-09-29 | 2003-10-15 | Glaxo Group Ltd | Compuestos utiles en el tratamiento de enfermedades inflamatorias. |
| US20020132803A1 (en) | 2001-01-05 | 2002-09-19 | Mahendra Dedhiya | Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| JP2004526720A (ja) | 2001-03-08 | 2004-09-02 | グラクソ グループ リミテッド | βアドレナリン受容体のアゴニスト |
| DE60224172T2 (de) | 2001-03-22 | 2008-12-04 | Glaxo Group Ltd., Greenford | Formanilid-derivative als beta2-adrenorezeptor-agonisten |
| UA77656C2 (en) * | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| AU2002303425A1 (en) | 2001-04-24 | 2002-11-05 | Epigenesis Pharmaceuticals, Inc. | Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent |
-
2002
- 2002-09-11 US US10/241,658 patent/US6777400B2/en not_active Expired - Fee Related
-
2003
- 2003-09-09 WO PCT/EP2003/010259 patent/WO2004024745A2/en not_active Ceased
- 2003-09-09 AU AU2003266390A patent/AU2003266390A1/en not_active Abandoned
- 2003-09-09 JP JP2004535514A patent/JP2006502172A/ja active Pending
- 2003-09-09 EP EP03795016A patent/EP1569951A2/en not_active Withdrawn
-
2004
- 2004-05-25 US US10/853,500 patent/US20040220156A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006502172A5 (enExample) | ||
| JP2005537278A5 (enExample) | ||
| JP5610766B2 (ja) | グリチルレチン酸誘導体 | |
| EP3357513B1 (en) | Pharmaceutical composition and application thereof | |
| CN103037692B (zh) | 用于抑制肌萎缩的方法 | |
| ES2707596T3 (es) | Uso de un agente modificador de hormonas suprarrenales | |
| JP5513660B2 (ja) | 結晶の差異評価への表面自由エネルギーの使用、表面自由エネルギーを指標として評価される結晶及び該結晶を含有してなる医薬組成物 | |
| TW200900058A (en) | N-(heteroaryl)-1-heteroaryl-1H-indole-2-carboxamide derivatives, their preparation and their therapeutic application | |
| EP2298315A1 (en) | Therapeutic treatment methods | |
| EP0221753A2 (en) | Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters | |
| BR112020007183A2 (pt) | tratamento de glomeruloesclerose focal segmentado com antagonistas de ccr2 | |
| CN102548964A (zh) | 不抑制肾上腺皮质类固醇合成的依托咪酯类似物 | |
| JP2020507610A (ja) | 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法 | |
| JP2016540795A (ja) | エーテル側鎖を有するキラルなｎ−置換イミダゾールカルボキシルエステル化合物、その製造方法及び用途 | |
| TW200914442A (en) | Gamma secretase modulators | |
| TWI226831B (en) | Pharmaceutical composition for ameliorating an undesirable anxiety state in a mammal | |
| Lefer | Corticosteroid antagonism of the positive inotropic effect of ouabain | |
| CN104447770A (zh) | 阿塞那平化合物 | |
| EP3849976A1 (en) | A gaba a receptor ligand | |
| JP5301474B2 (ja) | ４−［２−（４−メチルフェニルスルファニル）フェニル］ピペリジン塩の液体製剤 | |
| US9994534B2 (en) | Pain-relieving compositions and uses therefor | |
| WO2010065571A1 (en) | Treatment for glomerulonephritis with 2 - [ 4- ( -7-ethyl-5h-pyrrolo [ 2,3-b ] -pyrazin- 6 -yl) propan-2-ol | |
| US12428424B2 (en) | Estrogen receptor-modulating compounds | |
| AU2009266408C1 (en) | Pain-relieving compositions of furoxan NO donors and uses thereof | |
| JP2019518080A (ja) | 抹消性ｎｍｄａ受容体アンタゴニストとしての新規なジゾシルピン誘導体 |